BioSpace News Archive

PolarityTE, Inc. (Nasdaq: PTE) today announced that it has submitted its complete response to the U.S. Food and Drug Administration’s (FDA) clinical hold correspondence regarding its Investigational New Drug (IND) Application for SkinTE® with a proposed indication for chronic cutaneous ulcers.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the Nature Communications publication characterizing the novel splicing mechanism induced by compounds identified from the Huntington Disease (HD) program.

Acquisition provides opportunity to develop cladribine in generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD).

BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Jay M. Short, Ph.D., Chief Executive Officer, and Scott Smith, President, with participation by other BioAtla executives, will present at the 40th Annual J.P. Morgan Virtual Healthcare Conference.

OrganOx, a world leader in normothermic machine perfusion (NMP), today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of its metra system.

Amid accelerated demand for its dental artificial intelligence software, Overjet announced it has raised $42.5 million in Series B financing led by General Catalyst and Insight Partners with participation from existing investors Crosslink Capital and the MIT-affiliated E14 Fund in an oversubscribed round.

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, has successfully raised an aggregate $470 million of equity and debt financing in 2021, with $300 million in new debt financing from NantCapital, LLC.

Interleukin-2 is a pro-inflammatory cytokine whose role in Alzheimer’s Disease is not very well established, particularly given the multiplicity of bio factors implicated in this devastating disease.

I believe ongoing communications with you is my responsibility; therefore, I wanted to take this opportunity to review our accomplishments over the past year and provide some insight on what we expect to come in the new year.

Arcadia Biosciences, Inc. announced it has appointed Kevin Comcowich, current Chairman of the Arcadia Board of Directors, as interim chief executive officer, effective January 1, 2022.